{"id":"W2948740360","doi":"10.1038/s41591-019-0448-9","title":"Dabrafenib, trametinib and pembrolizumab or placebo in BRAF-mutant melanoma","year":2019,"lang":"en","type":"article","venue":"Nature Medicine","topic":"Melanoma and MAPK Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":323,"is_retracted":false,"has_abstract":false,"ca_institutions":"Université Laval; Centre hospitalier universitaire de Québec","funders":"Merck Sharp and Dohme","keywords":"Dabrafenib; Trametinib; Pembrolizumab; Melanoma; Medicine; Mutant; Cancer research; Oncology; Internal medicine; Vemurafenib; Biology; Immunotherapy; Metastatic melanoma; Genetics; MAPK/ERK pathway; Cancer; Phosphorylation; Gene","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002692339,0.0001915097,0.0002878423,0.0000899418,0.00002419442,0.000007087542,0.0001601653,0.0004585745,0.0002521366],"category_scores_gemma":[0.0002379393,0.0001268656,0.00003166889,0.0001303794,0.00007875059,0.000003542676,0.00006908543,0.0003807806,0.00001709737],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00001208632,"about_ca_system_score_gemma":0.00007191191,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0000220766,"about_ca_topic_score_gemma":0.0001307109,"domain_scores_codex":[0.9988576,0.00005820324,0.0002224838,0.000420418,0.0001777629,0.0002635841],"domain_scores_gemma":[0.9994159,0.00003893359,0.00006286393,0.0003360267,0.00003568506,0.0001105285],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","study_design_scores_codex":[0.001489889,0.00006627198,0.009792275,0.0001044483,0.00003766956,0.0001053412,0.0002337041,0.000002259604,0.9778183,0.0005505081,0.004946956,0.004852421],"study_design_scores_gemma":[0.03385881,0.006605373,0.06111197,0.0004405701,0.00008961878,0.001218236,0.000819965,0.0002196475,0.4112166,0.0003472147,0.4830629,0.001009078],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9843881,0.003173899,0.00002894483,0.0008858199,0.0004626727,0.0003580381,0.00001048647,0.00001400502,0.0106781],"genre_scores_gemma":[0.995306,0.0002428435,0.0001365255,0.00113057,0.0004135468,0.0000124188,0.00009282918,0.00002270161,0.002642629],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.5666016,"threshold_uncertainty_score":0.5173428,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.005862682673053842,"score_gpt":0.2530370359029938,"score_spread":0.24717435322994,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}